<p>在昨天發佈的一份報告中，摩根大通的 Anupam Rama 維持了對 Erasca 的買入評級，目標價為 23.00 美元。該公司的股票昨天收盤價為 10.46 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以便做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
<p>Rama 覆蓋醫療保健行業，關注的股票包括 Sarepta Therapeutics、Travere Therapeutics 和 Erasca。根據 TipRanks 的數據，Rama 的平均回報率為 23.7%，推薦股票的成功率為 52.03%。</p>
<p>除了摩根大通，Erasca 還在 5 月 12 日獲得了瑞穗證券的 Joseph Catanzaro 的買入評級。然而，在同一天，美國銀行證券重申了對 Erasca（NASDAQ: ERAS）的賣出評級。</p>

ERAS

基因改革 ETF - ARK

標普全球醫療股指數 ETF - iShares

<p>摩根大通分析師 Anupam Rama 對 Erasca（ERAS）維持了買入評級，目標價為 23.00 美元，而該股收盤價為 10.46 美元。Rama 的推薦平均回報率為 23.7%，成功率為 52.03%。瑞穗證券也對 Erasca 發佈了買入評級，但美國銀行證券在同一天重申了賣出評級</p>

<p>In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Erasca, with a price target of $23.00. The company’s shares closed yesterday at $10.46.</p>
<div class="lb-trans"><p>在昨天發佈的一份報告中，摩根大通的 Anupam Rama 維持了對 Erasca 的買入評級，目標價為 23.00 美元。該公司的股票昨天收盤價為 10.46 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以便做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
</div><p>Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Travere Therapeutics, and Erasca. According to TipRanks, Rama has an average return of 23.7% and a 52.03% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Rama 覆蓋醫療保健行業，關注的股票包括 Sarepta Therapeutics、Travere Therapeutics 和 Erasca。根據 TipRanks 的數據，Rama 的平均回報率為 23.7%，推薦股票的成功率為 52.03%。</p>
</div><p>In addition to J.P. Morgan, Erasca also received a Buy from Mizuho Securities’s Joseph Catanzaro in a report issued on May 12. However, on the same day, Bank of America Securities reiterated a Sell rating on Erasca (NASDAQ: ERAS).</p>
<div class="lb-trans"><p>除了摩根大通，Erasca 還在 5 月 12 日獲得了瑞穗證券的 Joseph Catanzaro 的買入評級。然而，在同一天，美國銀行證券重申了對 Erasca（NASDAQ: ERAS）的賣出評級。</p>
</div>

J.P. Morgan Keeps Their Buy Rating on Erasca (ERAS)

Tip Ranks

Erasca

醫療業 ETF - Vanguard

納斯達克生物科技指數 ETF - iShares Nasdaq

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 3 倍做多 - Direxion

2 倍做多納斯達克生物技術 ETF - ProShares

生物科技 ETF - VanEck Vectors

美國制藥 ETF - iShares

標普生物技術 ETF - SPDR

醫藥突破 ETF - ALPS

動態生物技術與基因組 ETF - Invesco

醫療業 ETF - SPDR

摩根大通

Sarepta醫療

Travere Therapeutics

瑞穗金融集團

Mizuho Financial Group, Inc.

美國銀行

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

摩根大通維持對 Erasca (ERAS) 的買入評級